NexMed To Present at the Rodman & Renshaw 12th Annual Healthcare Conference
August 25 2010 - 11:00AM
Business Wire
NexMed, Inc. (Nasdaq: NEXM), backed by a revenue generating CRO
business and seeking to leverage its proprietary, multi-route
NexACT® drug delivery technology and internal pipeline through
out-licensing arrangements and partnerships, today announced that
Dr. Bassam Damaj, President and Chief Executive Officer, will
present at the Rodman & Renshaw 12th Annual Healthcare
Conference at 10:25am ET on Tuesday, September 14, 2010, in the
Winslow Salon on the 5th floor of the New York Palace Hotel in New
York City.
The Company’s presentation will be available via webcast and can
be accessed at: http://www.wsw.com/webcast/rrshq18/nexm.
About NexMed,
Inc.
Backed by a solid, revenue generating CRO business, NexMed has
leveraged the flexibility of its proven NexACT® drug delivery
technology to enable multi-route administration of new and improved
compounds across numerous therapeutic classes. Future growth will
be driven primarily through out-licensing of this technology for
the development and commercialization of such compounds to
pharmaceutical and biotechnology companies, worldwide.
Concurrently, the Company is seeking to monetize its existing
product pipeline, including compounds from pre-clinical through
Phase 3, currently focused on dermatology, sexual dysfunction and
cancer. For further information on NexMed and its subsidiaries,
visit the following websites: http://www.nexmed.com or
http://www.bio-quant.com.
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From Aug 2023 to Aug 2024